Researchers have found a previously unknown mutation in the factor VIII (FVIII) gene that accelerates blood clotting . This discovery could eventually open the door to new therapies for hemophilia A, according to a report published in the New England Journal of Medicine.

Hemophilia A is a genetic disorder where patients lack enough FVIII, a protein essential for normal blood clotting. Without enough FVIII, people can experience repeated bleeding episodes, often in the joints and muscles, which can cause long-term disability.

Current treatments focus on replacing the missing FVIII protein, but researchers have long been exploring whether naturally occurring mutations could provide alternative therapeutic strategies.

While prophylactic treatment is the standard treatment for severe hem

See Full Page